ClearBridge Large Cap Growth Strategy highlights Eli Lilly and Company (LLY) as a compelling growth equity, citing robust revenue expansion, a diversified diabetes and obesity drug portfolio, and a strong pipeline advancing into oncology and neurology. The firm underscores LLY’s leadership in GLP-1 therapeutics and its long-term value proposition.
- LLY generated $32.8 billion in revenue in 2024, up 21% YoY
- Mounjaro sales exceeded $10.5 billion in 2024
- Operating margin at 38.5% in 2024
- Pipeline includes Phase 3 trials for Alzheimer’s (LY3298176) and oncology (LY3462228)
- $1.5 billion manufacturing expansion in Indianapolis
- Projected revenue of $58 billion by 2027
Eli Lilly and Company (LLY) has emerged as a top-tier holding within the ClearBridge Large Cap Growth Strategy, driven by consistent revenue growth and leadership in metabolic disease therapeutics. The firm notes that LLY reported $32.8 billion in revenue for fiscal year 2024, a 21% year-over-year increase, fueled primarily by its GLP-1-based medications, including Mounjaro (tirzepatide) and Zepbound (tirzepatide for weight management). Mounjaro’s global sales exceeded $10.5 billion in 2024, marking a key driver of the company’s performance. The strategy emphasizes LLY’s diversified therapeutic pipeline, which includes ongoing Phase 3 trials for LY3298176 in Alzheimer’s disease and LY3462228 in oncology. These programs are seen as high-potential catalysts for future growth, particularly in the neurodegenerative and cancer therapy spaces. Additionally, the company’s investment in manufacturing capacity, including a $1.5 billion expansion at its facility in Indianapolis, supports its ability to meet rising global demand. ClearBridge highlights LLY’s strong balance sheet, with $12.3 billion in cash and equivalents and $18.7 billion in total debt, reflecting a manageable leverage profile. The company’s operating margin reached 38.5% in 2024, demonstrating efficient cost management amidst significant R&D expenditures. Analysts project LLY’s revenue to reach $58 billion by 2027, underpinning the firm’s long-term constructive view. Market participants, including institutional investors and analysts, are closely monitoring LLY’s trajectory as it expands into new therapeutic areas. The firm’s continued innovation in weight-loss and diabetes treatments positions it as a cornerstone in the biopharmaceutical sector, with potential implications for healthcare providers, insurers, and patients seeking advanced treatment options.